DUPLEX (2023) — Trial Summary
DUPLEX (2023): The DUPLEX phase 3 trial evaluated sparsentan, a dual endothelin type A and angiotensin II receptor antagonist, versus irbesartan in patients with focal segmental glomerulosclerosis (FSGS).
References
- Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023;389(26):2436-2445.